Evicenter
P&T meetings

Molgramostim Inhalation Solution

Autoimmune pulmonary alveolar proteinosis

Manufacturer
Savara
Regulatory submission
BLA resubmitted December 2025
Launch
Not announced
Last updated
89 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Limitations of current therapies

1 evidence topic · 4 sources

Summary

Whole lung lavage can restore alveolar function but does not cure the disease. The ERS recommendation for inhaled GM-CSF is strong, but its stated evidence certainty is very low. Relapse during inhaled GM-CSF dose de-escalation has been reported. Indirect comparisons of sargramostim and molgramostim are exploratory and do not establish clinical equivalence.